References
- Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995; 99(6B): 3–7S
- Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331(6): 377–82
- Dever LA, Dermody TS. Mechanisms of bacterial resistance to antibiotics. Arch Intern Med 1991; 151 (5): 886–95
- Barry AL, Pfaller MA, Fuchs PC, et al. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US Medical Centers in 1992 and 1993. Antimicrob Agents Chemother 1994; 38(10): 2419–25
- Thornsberry C, Ogilvie P, Kahn J, et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996–1997 respiratory season. Diagn Microbiol Infect Dis 1997; 29: 249–57
- Jacoby GA, Archer GL. New mechanisms of bacterial resistance to antimicrobial agents. N Engl J Med 1991; 324(9): 601–12
- Schatz BS, Karavokiros KT, Taeubel MA, et al. Comparison of cefprozil, Cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. Ann Pharmacother 1996; 30(3): 258–68
- Pankuch GA, Visalli MA, Jacobs MR, et al. Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1995; 39(7): 1499–504
- Barry AL, Pfaller MA, Fuchs PC. The antibacterial activity of co-amoxiclav. (Letter) J Antimicrob Chemother 1993; 31(4): 612–5
- Lower Respiratory Tract Infection Collaborative Study Group. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Clin Infect Dis 1997; 24(4): 570–4
- Doern G V, Brueggemann AB, Pierce G, et al. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40(12): 2884–6
- Doern GV, Brueggemann AB, Pierce G, et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother 1997; 41(2): 292–7
- Perez-Trallero E, Garcia-Arenzana JM, Jimenez JA, et al. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. (Letter) Eur J Clin Microbiol Infect Dis 1990; 9(12): 905–6
- Richard P, Gutmann L. Sparfloxacin and other new fluoroquinolones. J Antimicrob Chemother 1992; 30(6): 739–44
- Wise R, Honeybourne D. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J Antimicrob Chemother 1996; 37(Suppl A): 57–63
- Aubier M, Lode H, Gialdroni-Grassi G, et al. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. J Antimicrob Chemother 1996; 37(Suppl A): 73–82
- Rubinstein E. Safety profile of Sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother 1996; 37 Suppl A: 145–60
- Ernst ME, Ernst EJ, Klepser ME. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? Am J Health Syst Pharm 1997; 54(22): 2569–84
- Beringer PM, Holtom PD, Rho JP. Comparing the newest fluoroquinolones: levofloxacin and sparfloxacin. Formulary 1997; 32(Sept): 926–43
- Wagstaff AJ, Balfour JA. Grepafloxacin. Drugs 1997; 53(5): 817–24